BCAX
Bicara Therapeutics Inc.
Price Chart
Latest Quote
$23.12
-0.31 (-1.32%)
Current Price
| Previous Close | $23.43 |
| Open | $23.36 |
| Day High | $23.50 |
| Day Low | $22.61 |
| Volume | 511,964 |
Stock Information
| Shares Outstanding | 66.17M |
| Total Debt | $1.16M |
| Cash Equivalents | $497.26M |
| Net Income | $-185.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.53B |
| EPS (TTM) | $-3.07 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.03B |
| Income | $-185.36M |
| Book/sh | $7.11 |
| Cash/sh | $7.51 |
| Employees | 103 |
Financial Ratios
| Quick Ratio | 11.44 |
| Current Ratio | 11.59 |
| Debt/Eq | 0.25 |
Returns & Margins
| ROA | -26.14% |
| ROE | -41.01% |
Ownership
| Insider Ownership | 10.07% |
| Institutional Ownership | 107.71% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.73 |
| P/B | 3.25 |
Analyst Data
| Recommendation | buy |
| Target Price | $33.50 |
Technical Indicators
| SMA20 | $24.99 |
| SMA50 | $26.60 |
| SMA200 | $20.84 |
| RSI | 46.59 |
| ATR | 1.3412 |
| Shares Float | 36.90M |
| Short Float | 22.02% |
| Short Ratio | 17.09 |
| Rel Volume | 0.78 |
Performance History
| Week | -1.95% |
| Month | -14.69% |
| Quarter | +12.12% |
| 6 Months | +31.44% |
| YTD | +41.15% |
| Year | +94.12% |
| 10 Years | -1.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $23.12 | 511,964 |
| 2026-08-28 | $23.43 | 524,700 |
| 2026-08-27 | $24.83 | 445,000 |
| 2026-08-26 | $24.73 | 423,800 |
| 2026-08-25 | $24.58 | 410,300 |
| 2026-08-24 | $23.58 | 669,700 |
| 2026-08-21 | $23.90 | 496,300 |
| 2026-08-20 | $24.39 | 449,000 |
| 2026-08-19 | $25.86 | 670,400 |
| 2026-08-18 | $24.92 | 446,100 |
| 2026-08-17 | $24.94 | 434,600 |
| 2026-08-14 | $24.28 | 479,900 |
| 2026-08-13 | $23.63 | 751,500 |
| 2026-08-12 | $24.63 | 810,300 |
| 2026-08-11 | $23.76 | 1,716,300 |
| 2026-08-10 | $27.73 | 949,300 |
| 2026-08-07 | $28.06 | 570,600 |
| 2026-08-06 | $27.51 | 704,000 |
| 2026-08-05 | $25.89 | 818,300 |
| 2026-08-04 | $26.10 | 815,100 |
| 2026-08-03 | $25.74 | 399,000 |
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
đ° Latest News
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
Insider Monkey âĸ 2026-08-19T13:56:16Z
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
Motley Fool âĸ 2026-08-18T15:13:34Z
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)
Simply Wall St. âĸ 2026-08-13T10:10:59Z
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
MT Newswires âĸ 2026-08-11T17:28:59ZBicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary
Moby âĸ 2026-08-11T17:15:47Z
Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances
InvestorsHub âĸ 2026-08-11T14:17:37Z
Bicara Therapeutics Q2 Earnings Call Highlights
MarketBeat âĸ 2026-08-11T14:04:35Z
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Motley Fool âĸ 2026-06-13T05:21:24Z
Bicara (BCAX) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-06-01T16:13:09Z
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
MarketBeat âĸ 2026-05-22T15:09:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $155,604,000 | $82,389,000 | $39,889,000 | $37,656,000 |
| Net Non Operating Interest Income Expense | $17,871,000 | $14,581,000 | $1,314,000 | $-108,000 |
| Operating Expense | $155,604,000 | $82,389,000 | $39,889,000 | $37,656,000 |
| General And Administrative Expense | $30,508,000 | $18,770,000 | $9,272,000 | $6,344,000 |
| Interest Expense | - | - | $0 | $112,000 |
| Other Income Expense | - | - | $-13,405,000 | $-80,000 |
| Other Non Operating Income Expenses | - | - | $-13,405,000 | $-80,000 |
| Interest Expense Non Operating | - | - | $0 | $112,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Net Interest Income | $17,871,000 | $14,581,000 | $1,314,000 | $-108,000 |
| Interest Income | $17,871,000 | $14,581,000 | $1,314,000 | $4,000 |
| Normalized Income | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Net Income From Continuing And Discontinued Operation | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Total Operating Income As Reported | $-155,604,000 | $-82,389,000 | $-39,889,000 | $-37,656,000 |
| Net Income Common Stockholders | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Net Income | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Net Income Including Noncontrolling Interests | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Net Income Continuous Operations | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Pretax Income | $-137,733,000 | $-67,808,000 | $-51,980,000 | $-37,844,000 |
| Interest Income Non Operating | $17,871,000 | $14,581,000 | $1,314,000 | $4,000 |
| Operating Income | $-155,604,000 | $-82,389,000 | $-39,889,000 | $-37,656,000 |
| Per Share | ||||
| Diluted EPS | $-2.52 | $-4.05 | $-1.53 | $-2.45 |
| Basic EPS | $-2.52 | $-4.05 | $-1.53 | $-2.45 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-155,499,000 | $-82,333,000 | $-39,870,000 | $-37,722,000 |
| Reconciled Depreciation | $105,000 | $56,000 | $19,000 | $10,000 |
| EBITDA (Bullshit earnings) | $-155,499,000 | $-82,333,000 | $-39,870,000 | $-37,722,000 |
| EBIT | $-155,604,000 | $-82,389,000 | $-39,889,000 | $-37,732,000 |
| Diluted Average Shares | $54,676,896 | $16,805,524 | $33,984,930 | $15,440,460 |
| Basic Average Shares | $54,676,896 | $16,805,524 | $33,984,930 | $15,440,460 |
| Diluted NI Availto Com Stockholders | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Tax Provision | $217,000 | $187,000 | $5,000 | $1,000 |
| Research And Development | $125,096,000 | $63,619,000 | $30,617,000 | $31,312,000 |
| Selling General And Administration | $30,508,000 | $18,770,000 | $9,272,000 | $6,344,000 |
| Other Gand A | $9,926,000 | $6,225,000 | $9,272,000 | $2,544,000 |
| Salaries And Wages | $20,582,000 | $12,545,000 | $5,820,000 | $3,800,000 |
Fetched: 2026-08-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Total Assets | $430,994,000 | $509,996,000 | $233,982,000 | $6,703,000 |
| Total Non Current Assets | $8,941,000 | $7,463,000 | $2,909,000 | $1,719,000 |
| Other Non Current Assets | $6,910,000 | $6,618,000 | $2,094,000 | $1,083,000 |
| Current Assets | $422,053,000 | $502,533,000 | $231,073,000 | $4,984,000 |
| Other Current Assets | $7,252,000 | $12,822,000 | $633,000 | $826,000 |
| Cash Cash Equivalents And Short Term Investments | $414,801,000 | $489,711,000 | $230,440,000 | $4,158,000 |
| Cash And Cash Equivalents | $96,685,000 | $489,711,000 | $230,440,000 | $4,158,000 |
| Debt | ||||
| Total Debt | $1,710,000 | $738,000 | $657,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $593,000 | $131,000 | $372,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,117,000 | $607,000 | $285,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,542,000 | $18,121,000 | $382,751,000 | $105,506,000 |
| Total Non Current Liabilities Net Minority Interest | $593,000 | $131,000 | $367,666,000 | $81,610,000 |
| Current Liabilities | $28,949,000 | $17,990,000 | $15,085,000 | $23,896,000 |
| Payables And Accrued Expenses | $22,791,000 | $14,300,000 | $13,058,000 | $22,720,000 |
| Payables | $7,793,000 | $4,508,000 | $3,186,000 | $5,137,000 |
| Accounts Payable | $7,793,000 | $4,508,000 | $3,186,000 | $5,137,000 |
| Other Non Current Liabilities | - | - | $17,000 | $85,000 |
| Interest Payable | - | - | $0 | $1,000 |
| Equity | ||||
| Common Stock Equity | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Total Equity Gross Minority Interest | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Stockholders Equity | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Gains Losses Not Affecting Retained Earnings | $243,000 | $0 | - | - |
| Other Equity Adjustments | $243,000 | - | - | - |
| Retained Earnings | $-358,966,000 | $-221,016,000 | $-153,021,000 | $-101,036,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $367,277,000 | $81,525,000 |
| Other | ||||
| Ordinary Shares Number | $56,600,724 | $54,440,013 | $51,760,925 | $51,760,925 |
| Share Issued | $56,600,724 | $54,440,013 | $51,760,925 | $51,760,925 |
| Tangible Book Value | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Invested Capital | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Working Capital | $393,104,000 | $484,543,000 | $215,988,000 | $-18,912,000 |
| Capital Lease Obligations | $1,710,000 | $738,000 | $657,000 | $0 |
| Total Capitalization | $401,452,000 | $491,875,000 | $-148,769,000 | $-98,803,000 |
| Additional Paid In Capital | $760,168,000 | $712,884,000 | $4,250,000 | $2,231,000 |
| Capital Stock | $7,000 | $7,000 | $2,000 | $2,000 |
| Common Stock | $7,000 | $7,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $593,000 | $131,000 | $372,000 | $0 |
| Current Capital Lease Obligation | $1,117,000 | $607,000 | $285,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,041,000 | $3,083,000 | $1,742,000 | $1,176,000 |
| Current Accrued Expenses | $14,998,000 | $9,792,000 | $9,872,000 | $17,583,000 |
| Net PPE | $2,031,000 | $845,000 | $815,000 | $636,000 |
| Gross PPE | $2,031,000 | $845,000 | $815,000 | $636,000 |
| Other Properties | $2,031,000 | $845,000 | $815,000 | $636,000 |
| Other Short Term Investments | $318,116,000 | $0 | - | - |
Fetched: 2026-08-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-107,114,000 | $-74,822,000 | $-46,214,000 | $-32,268,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-106,834,000 | $-74,751,000 | $-45,628,000 | $-32,076,000 |
| Cash Flow From Continuing Operating Activities | $-106,834,000 | $-74,751,000 | $-45,628,000 | $-32,076,000 |
| Investing Activities | ||||
| Capital Expenditure | $-280,000 | $-71,000 | $-586,000 | $-192,000 |
| Investing Cash Flow | $-318,453,000 | $-9,000 | $-586,000 | $-192,000 |
| Cash Flow From Continuing Investing Activities | $-318,453,000 | $-9,000 | $-586,000 | $-192,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $29,498,000 | $332,427,000 | $272,347,000 | $31,535,000 |
| Financing Cash Flow | $32,261,000 | $334,031,000 | $272,496,000 | $31,695,000 |
| Cash Flow From Continuing Financing Activities | $32,261,000 | $334,031,000 | $272,496,000 | $31,695,000 |
| Net Common Stock Issuance | $29,498,000 | $332,427,000 | $0 | - |
| Common Stock Issuance | $29,498,000 | $332,427,000 | $0 | - |
| Net Preferred Stock Issuance | - | $0 | $272,347,000 | $31,535,000 |
| Preferred Stock Issuance | - | $0 | $272,347,000 | $31,535,000 |
| Other | ||||
| End Cash Position | $96,685,000 | $489,711,000 | $230,440,000 | $4,158,000 |
| Beginning Cash Position | $489,711,000 | $230,440,000 | $4,158,000 | $4,731,000 |
| Changes In Cash | $-393,026,000 | $259,271,000 | $226,282,000 | $-573,000 |
| Proceeds From Stock Option Exercised | $2,763,000 | $1,604,000 | $149,000 | $160,000 |
| Net Investment Purchase And Sale | $-318,173,000 | $0 | - | - |
| Purchase Of Investment | $-318,173,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-280,000 | $-9,000 | $-586,000 | $-192,000 |
| Sale Of PPE | $0 | $62,000 | $0 | - |
| Purchase Of PPE | $-280,000 | $-71,000 | $-586,000 | $-192,000 |
| Change In Working Capital | $14,809,000 | $-14,132,000 | $-9,624,000 | $4,949,000 |
| Change In Other Current Liabilities | $-932,000 | $81,000 | $-47,000 | $0 |
| Change In Payables And Accrued Expense | $10,460,000 | $2,637,000 | $-8,663,000 | $5,871,000 |
| Change In Prepaid Assets | $5,281,000 | $-16,850,000 | $-914,000 | $-922,000 |
| Other Non Cash Items | $895,000 | $-77,000 | $13,495,000 | - |
| Stock Based Compensation | $15,006,000 | $7,397,000 | $1,899,000 | $810,000 |
| Amortization Of Securities | $301,000 | $0 | - | - |
| Depreciation Amortization Depletion | $105,000 | $56,000 | $19,000 | $10,000 |
| Depreciation And Amortization | $105,000 | $56,000 | $19,000 | $10,000 |
| Depreciation | $105,000 | $56,000 | $19,000 | $10,000 |
| Net Income From Continuing Operations | $-137,950,000 | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Asset Impairment Charge | - | $0 | $568,000 | $0 |
| Income Tax Paid Supplemental Data | - | - | $0 | $1,000 |
Fetched: 2026-08-21